Abstract

AimNon-alcoholic fatty liver disease (NAFLD) is a health burden worldwide, which is closely related to obesity. The effect of sleeve gastrectomy (SG) on NAFLD is efficient, and the underlying mechanism remains unknown. Our study sought to investigate the mechanism of dual-specificity protein phosphatase 1 (DUSP1) expression regulation following the SG procedure in NAFLD patients and C57BL/6J mice via miR-200c-3p.MethodsThe serum was extracted from NAFLD patients who underwent laparoscopic sleeve gastrectomy (LSG) and volunteers. Next, the correlation between miR-200c-3p and DUSP1 was identified in vitro. NAFLD mice were modelled by high-fat diets (HFD). The hepatic tissue expression levels of miR-200c-3p, DUSP1, phospho-extracellular regulated protein kinases1/2 (p-ERK1/2), phospho -p38 mitogen-activated protein kinases (p-p38), and phospho-c-Jun N-terminal kinases (p-JNK) induced by SG procedure were evaluated.ResultsThe SG procedure contributed to significant weight loss, reduced lipids in NAFLD patients and mice. The increased expression level of miR-200c-3p and reduced expression of DUSP1 were observed in NAFLD patients and mice (p<0.05). The reduced expression levels of miR-200c-3p and increased expression of DUSP1 were observed in patients and mice with NAFLD who underwent SG procedure. DUSP1 is a potential target of miR-200c-3p.ConclusionsA novel mechanism was identified in which miR-200c-3p regulates the MAPK-dependent signals that are linked to the promotion of hepatosteatosis via DUSP1 after sleeve gastrectomy. The findings suggested that miR-200c-3p should be further explored as a potential target for the treatments of NAFLD.

Highlights

  • NAFLD is the most common cause of liver disease worldwide, considered the hepatic manifestation of metabolic syndrome associated with obesity, insulin resistance (IR), dyslipidemia, diabetes, and heredity [1]

  • This study aims to investigate the mechanism of dualspecificity protein phosphatase 1 (DUSP1) expression regulation following the sleeve gastrectomy (SG) procedure in NAFLD patients and C57BL/6J mice via miR-200c-3p

  • We demonstrated that miR-200c-3p regulates DUSP1 expression in the HepG2 cell line, and its expression was increased in NAFLD patients and mice

Read more

Summary

Introduction

NAFLD is the most common cause of liver disease worldwide, considered the hepatic manifestation of metabolic syndrome associated with obesity, insulin resistance (IR), dyslipidemia, diabetes, and heredity [1]. Obesity is an independent risk factor for NAFLD, and weight loss is the only safe and effective treatment for NAFLD [7, 8]. Sodium-glucose transporter 2 (SGLT2) inhibitors, lipase inhibitors, and Glucagon-like peptide 1 (GLP 1) receptor stimulants all have been reported weight reduction effects [11–13]. It is difficult for most obese patients to achieve and maintain an ideal state of body mass after lifestyle intervention and medical treatment, and surgical treatment should be considered

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call